Lorcaserin Hcl for the treatment of obesity

5-Hydroxytryptamine Medications for the Treatment of Obesity

(2015) L. K. Burke et al.   JOURNAL OF NEUROENDOCRINOLOGY

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

(2015) Xavier Pi-Sunyer et al.   NEW ENGLAND JOURNAL OF MEDICINE

5-HT Obesity Medication Efficacy via POMC Activation is Maintained During Aging

(2014) Luke K. Burke et al.   ENDOCRINOLOGY

Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes

(2014) Steven R. Smith et al.   Obesity

Safety and Efficacy of Lorcaserin: A Combined Analysis of the BLOOM and BLOSSOM Trials

(2014) Louis Aronne et al.   POSTGRADUATE MEDICINE

Echocardiographic Assessment of Cardiac Valvular Regurgitation With Lorcaserin From Analysis of 3 Phase 3 Clinical Trials

(2013) Neil J. Weissman et al.   Circulation-Cardiovascular Imaging

Lorcaserin: A Review of its Use in Chronic Weight Management

(2013) Sheridan M. Hoy   DRUGS

Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis

(2013) Eric D. Berglund et al.   JOURNAL OF CLINICAL INVESTIGATION

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

(2013) Caroline M. Apovian et al.   Obesity

Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010

(2012) Katherine M. Flegal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study

(2012) Patrick M. O'Neil et al.   Obesity

Emerging pharmacotherapy for obesity

(2011) Louis J Aronne et al.   EXPERT OPINION ON EMERGING DRUGS

A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial

(2011) Meredith C. Fidler et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

(2011) Kishore M Gadde et al.   LANCET

Lorcaserin, A 5-HT2CReceptor Agonist, Reduces Body Weight by Decreasing Energy Intake without Influencing Energy Expenditure

(2010) Corby K. Martin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

5-HT2CRs expressed by pro-opiomelanocortin neurons regulate insulin sensitivity in liver

(2010) Yong Xu et al.   NATURE NEUROSCIENCE

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

(2010) Steven R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lorcaserin (APD356), a Selective 5-HT2CAgonist, Reduces Body Weight in Obese Men and Women

(2008) Steven R. Smith et al.   Obesity